Full Year 2023 Investor Presentation
123
Investor presentation
Full year 2023
Region China at a glance.
Region China
Million
Diabetes trend
Diabetes market by value and Novo
Nordisk market share
Novo Nordisk reported sales
DKK
billion
MS
Full year 2023
Sales
(mDKK)
Growth²
200
6%
14%
160
Injectable GLP-13
6,077
78%
50
30
100%
RybelsusⓇ
131
124%
GLP-1
82.9%1
80%
Total GLP-1
6,208
79%
120
20
20
Insulin
Total insulin4
8,848
-7%
-0.1%1
60%
175
80
164
141
10
Other Diabetes care5
892
-18%
40%
40
40
10
Diabetes care
15,948
13%
7.8%¹
OAD
Obesity care
146
17%
20%
Diabetes & Obesity care
16,094
13%
0
2021
0
0%
2030
2045
Population with diabetes
Diabetes growth rate
Nov
2018
Nov
2023
Rare disease?
Total
593
-26%
16,687
11%
GLP-1 MS
-Insulin MS
⚫OAD MS
Source: International Diabetes Federation: Diabetes Atlas 10th Edition 2021
Region China covers Mainland China, Taiwan, and Hong Kong
1 CAGR calculated for last 5-year period
Competitor insulin value market shares, as of Nov 2023: Novo Nordisk 51%,
Others 49%; Competitor GLP-1 value market shares, as of Nov 2023: Novo
Nordisk 77% and Others 23% OAD: Oral anti-diabetic; MS: Market Share;
Note: Market values are based on list prices; Source: IQVIA MAT, Nov 2023
value figures
2 At constant exchange rates; 3 Comprises VictozaⓇ and OzempicⓇ; 4
Comprises Tresiba®, XultophyⓇ, Levemir®, NovoMix®, Ryzodeg®, NovoRapidⓇ;
5Comprises Novo NormⓇ and needles; 6Comprises SaxendaⓇ; Comprises
primarily NovoSeven®, Novo Eight® and NorditropinⓇView entire presentation